Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...

Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an ...

Chronic immune-related adverse events occur in more than a third of patients with early-stage TNBC treated with pembrolizumab.

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...

Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has advised Intas ...

Under the terms of this agreement, Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the ...

During a live event, Moshe C. Ornstein, MD, MA, discussed the recommended regimens for non–clear cell renal cell carcinoma ...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study ...